For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Open Access
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have revolutionized the management of not only type 2 diabetes but also obesity. However, even with rapid therapeutic advances in GLP-1RAs, questions regarding the fundamental principles of GLP-1-mediated weight loss and the enhanced efficacy of next-generation therapies remain. In this comprehensive review article, we first examine the milestones of GLP-1, from its initial discovery and biological characterization to its successful translation into clinical therapy. Furthermore, this review highlights the latest clinical trial data, specifically HbA1c reduction, weight-loss efficacy, and safety profiles, while exploring current pipelines of major pharmaceutical companies. Additionally, we delineate the mechanistic principles underlying the efficacy of GLP-1 single- and multi-receptor agonists and address challenges in mitigating side effects of GLP-1RAs. Finally, we analyze the rapidly evolving landscape of next-generation, incretin-based combination therapies. With an abundance of GLP-1- related therapies already available or in development, we assess how future GLP-1 multi-receptor agonists can achieve enhanced efficacy and how leveraging weight-loss biology, such as set-point theory, can improve therapeutic outcomes.Keywords
This publication has 272 references indexed in Scilit:
- Long‐acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studiesObesity, 2025
- Glucagon-Like Peptide 1 Receptor Agonists and Mental HealthJAMA Psychiatry, 2025
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)Obesity, 2024
- Obesity Management in AdultsJAMA, 2023
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 DiabetesJAMA Network Open, 2023
- Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the USJAMA Health Forum, 2021
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 StudyThe Journal of Clinical Pharmacology, 2020
- Adaptive thermogenesis with weight loss in humansObesity, 2013